Professor Sir Rory Collins
Research groups
- ATLAS: International ATLAS (Adjuvant Tamoxifen Longer Against Shorter) Breast Cancer Treatment Trial
- ATT: Antithrombotic Trialists' Collaboration
- CTT: Cholesterol Treatment Trialists' Collaboration
- HPS3 / TIMI 55 - REVEAL : Randomised Evaluation of the Effects of Anacetrapib through Lipid-modification
- HPS: Heart Protection Study
- International Study of Infarct Survival (ISIS)
- Mexico City Prospective Study
- Oxford Cholesterol Study
- Prospective Studies Collaboration
- Research regulation
- SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
- The Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
- Trials methodology
- UK Biobank
Colleges
Websites
-
UK Biobank
Principal Investigator and Chief Execuitve
-
British Heart Foundation
Professor of Medicine and Epidemiology
-
Tokai University
Adjunctive Professor
-
China Oxford Centre for International Health Research
Honorary Director
-
Beijing Union Medical College and Chinese Academy of Medical Sciences
Honorary Professor
Rory Collins
FRS, FMedSci
Head of Department and BHF Professor of Medicine and Epidemiology
Rory Collins studied Medicine at St Thomas’s Hospital Medical School, London University (1974-1980), and Statistics at George Washington University (1976-7) and at the University of Oxford (1982-3).
In 1985 he became co-director, with Professor Sir Richard Peto, of the University of Oxford's Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU). In 1996, he was appointed Professor of Medicine and Epidemiology at Oxford, supported by the British Heart Foundation.
He became Principal Investigator and Chief Executive of the UK Biobank prospective study of 500,000 people in September 2005. From July 2013, he became the Head of the Nuffield Department of Population Health at Oxford University.
His work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer. He was knighted in 2011 for his services to science.
Key publications
-
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Journal article
Baigent C. et al, (2005), Lancet, 366, 1267 - 1278
-
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Journal article
Antithrombotic Trialists' Collaboration None., (2002), BMJ, 324, 71 - 86
-
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
Journal article
Heart Protection Study Collaborative Group None., (2002), Lancet, 360, 7 - 22
Recent publications
-
Risk prediction of ischemic heart disease using plasma proteomics, conventional risk factors and polygenic scores in Chinese and European adults.
Journal article
Mazidi M. et al, (2024), Eur J Epidemiol
-
Alcohol and mortality in Mexico: prospective study of 150 000 adults.
Journal article
Trichia E. et al, (2024), Lancet Public Health, 9, e907 - e915
-
Predictive value of 8-year blood pressure measures in intracerebral haemorrhage risk over 5 years.
Journal article
Zhang Y. et al, (2024), Eur J Prev Cardiol, 31, 1702 - 1710
-
Associations of polygenic risk scores with risks of stroke and its subtypes in Chinese.
Journal article
Yang S. et al, (2024), Stroke Vasc Neurol, 9, 399 - 406
-
One-size-fits-all versus risk-category-based screening interval strategies for cardiovascular disease prevention in Chinese adults: a prospective cohort study.
Journal article
Sun Z. et al, (2024), Lancet Reg Health West Pac, 49